2-(1-(5-chloro-2-methoxyphenyl)-5-methyl-1H-pyrazol-4-yl)-5-(3-fluorophenyl)-1,3,4-oxadiazole | 1198352-95-2

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 英文名称: 2-(1-(5-chloro-2-methoxyphenyl)-5-methyl-1H-pyrazol-4-yl)-5-(3-fluorophenyl)-1,3,4-oxadiazole
• 英文别名: 2-[1-(5-Chloro-2-methoxyphenyl)-5-methylpyrazol-4-yl]-5-(3-fluorophenyl)-1,3,4-oxadiazole
• CAS: 1198352-95-2
• 化学式: C₁₉H₁₄ClFN₄O₂
• 分子量: 384.797
• InChiKey: DMJOYPKVKLJUEE-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.1
• 重原子数：
  27
• 可旋转键数：
  4
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.11
• 拓扑面积：
  66
• 氢给体数：
  0
• 氢受体数：
  6

反应信息

• 作为产物：
  描述：

  1-(5-chloro-2-methoxyphenyl)-N'-(3-fluorobenzoyl)-5-methylpyrazole-4-carbohydrazide 在 三氯氧磷 作用下， 以70%的产率得到2-(1-(5-chloro-2-methoxyphenyl)-5-methyl-1H-pyrazol-4-yl)-5-(3-fluorophenyl)-1,3,4-oxadiazole
  参考文献：
  名称：

  Synthesis, characterization and antibacterial activity of 2-[1-(5-chloro-2-methoxy-phenyl)-5-methyl-1H-pyrazol-4-yl]-5-(substituted-phenyl)-[1,3,4]oxadiazoles

  摘要：

  In the present investigation a series of novel 2-[1-(5-chloro-2-methoxy-phenyl)-5-methyl-IH-pyrazol-4yl]-5-(substituted-phenyl)-[1,3,4]oxadiazoles (4a-j) were synthesized by cyclization of substituted-benzoic acid N'-[1-(5-chloro-2-methoxy-phenyl)-5-methyl-1H-pyrazole-4-carbonyl]-hydrazide by using phosphorousoxychloride at 120 degrees C. The chemical structure of the newly synthesized compounds was 13 characterized by analytical and spectral (IR, H-1 NMR, C-13 NMR and LC-MS) methods. The title compounds were screened for qualitative (zone of inhibition) and quantitative antibacterial activity (MIC) by agar cup plate and microtitration methods, respectively. Among the synthesized compounds in this series compound 2-[1-(5-chloro-2-methoxyphenyl)-5-methyl-1H-pyrazol-4-yl-5-(4-fluorophenyl)-1,3,4-oxadiazole (4b) was found to exhibit significant antibacterial activity with MICs of 22.4, 29.8, 29.6 and 30.0 mu g/mL against Bacillus subtilis, Staphylococcus aureus, Escherichia coli and Klebsiella pneumoniae, respectively. The other compounds exhibited moderate activity when compared to standard substance Ampicillin. (C) 2009 Elsevier Masson SAS. All rights reserved.

  DOI：

  10.1016/j.ejmech.2009.06.020